Kaye S B, Brampton M, Harper P, Smyth J, Kerr D J, Gore M, Green J A, Gilby E, Crawford S M, Rustin G J
Beatson Oncology Centre, Western Infirmary, Glasgow, UK.
Br J Cancer. 1992 Apr;65(4):624-5. doi: 10.1038/bjc.1992.127.
A total of 61 eligible patients with metastatic cancer have been treated in a series of Phase II trials of the novel pentacyclic pyrroloquinone, fosquidone. Tumour types were colorectal (23), renal (21), and non small cell lung (17). No patient had received prior chemotherapy. The drug was given intravenously as a 20 min infusion at the dose of 120 mg-2 on days 1 to 5 every 3 weeks. Treatment was well tolerated; the only significant side effects being mild nausea and generalised musculo-skeletal pains. Response was assessed after two cycles of therapy. No patient achieved an objective partial response. A total of nine patients demonstrated stable disease for a median duration of 11 weeks. Using this schedule of administration, fosquidone has no significant antitumour activity in this group of tumours.
在新型五环吡咯并醌类药物磷喹酮的一系列II期试验中，共有61例符合条件的转移性癌症患者接受了治疗。肿瘤类型包括结直肠癌（23例）、肾癌（21例）和非小细胞肺癌（17例）。所有患者此前均未接受过化疗。该药物通过静脉注射给药，每3周的第1至5天，以120 mg-2的剂量进行20分钟输注。治疗耐受性良好；唯一显著的副作用是轻度恶心和全身性肌肉骨骼疼痛。在两个治疗周期后评估疗效。没有患者达到客观部分缓解。共有9例患者病情稳定，中位持续时间为11周。按照这种给药方案，磷喹酮在这组肿瘤中没有显著的抗肿瘤活性。
